We're looking at a $3.08 long term POC, with around $5 POC if you include the crazy volume day it went up to ~$10 closed around $8. Bulls seem to have identified a support here and it's getting frothy off of no news! I think it's more and more investors catching wind of the Covid nasal spray preventive, along with the domination Auris has in ear, nose and throat...
Very little to be found on this one fundamentally, as to what the catalyst could be.
But SEC forms show numerous insiders (including CEO) buying before Christmas. Today, analyst Geulah Livshits from Chardan Capital released a buy rating with a PT of 33.
NPTH is significantly undervalued compared to peers:
- $33M mkt cap with $50M revenue in 2019
- < 1 EV/sales vs 18.24x industry avg
- Recent $12M financing at .90
- Insider options at .87 + open market buys
- In major historical support zone
The most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash...
VXL is the volume leader on TSX-V today on the news of Coronavirus vaccine patent application.
+21.74% so far. Likely held down by warrant sellers but could be a serious runner once they are out.
$12M mkt cap is cheap compared to other biomed stocks that ran on Coronavirus related news.
Very decent float at 89M shares.
Significant volume up tick on the daily chart. The pullback is now clean resulting from a follow through candle breaching the 0.618 fib- however I'm giving it the benefit of the doubt only because the increase in relative volume is significant. Watching for a 5 wave structure to take price action into 0.11
BPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact...
On October 18th, 2019, the FDA approved Amzeeq, otherwise known as FMX101 for the Israel based pharmaceutical company, Foamix. Amzeeq happens to be the first and only topical monocyline treatment to be used on acne patients. In anticipation of approval for this new product, shares of FOMX rallied from $2.53 per share on 10/08/2019 all the way up to highs around...
Hey everyone,
Moving away from the typical crypto posts today.
We are checking out MRK.
This stock has seen some hefty losses in the past few days, pushing the RSI into a oversold area
The increasing bear volume has not been supportive, and the price is breaking past the .382 fib level.
The stock is looking to find support, but the last few days have not...
Initial move of around 100% has had some time to consolidate and soak away remaining supply which has been thinning considerably since the first move. Recently the green bars have been finding much less supply therefore the possibility of a significant move is increasing. If the topside break occurs then 12.0c would be the target
This medical cannabis company...
It's about Quantum Materials Corp. (OTCQB:QTMM) a nanotechnology company that can make copious amounts of quantum dots. If you never heard of a quantum dot you are not alone. The average person doesn't understand, know if you can see them with the naked eye, how they are used or what they even are.
Quantum dots are man made crystals 10,000 times smaller than a...
